Regeneron Pharmaceuticals (REGN)
EBITDA Growth
6.06%
TTM · Period ending:
REGN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported6.06%period ending
Latest reported6.06%period ending
REGN TTM EBITDA YoY % (-66.67% → 6.06%)
Year-over-year change
High-resolution chart · PNG
REGN ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -265.4715% | |
| -103.4533% | |
| -55.3679% | |
| 8.8327% | |
| 41.0205% | |
| -23.7273% | |
| -118.5567% | |
| -1,315.7895% | |
| -8,033.3333% | |
| -258.1395% | |
| -203.125% | |
| 77.381% | |
| 97.3214% | |
| 60.5505% | |
| 71.4286% | |
| 13.4021% | |
| -47.3684% | |
| -109.6154% | |
| -348% | |
| -94% | |
| -11.7647% | |
| 67.5% | |
| 90% | |
| 84.0764% | |
| 81.7694% | |
| 57.2193% | |
| 31.3187% | |
| 0.6329% | |
| -32.2695% | |
| -69.2308% | |
| -121.9512% | |
| -120.979% | |
| -145.2174% | |
| -114.5631% | |
| -198.1818% | |
| -57.1429% | |
| -109.0909% | |
| -312% | |
| -66.6667% |